Experts comment the JUPITER trial in the latest NEJM issue

Experts around the globe comment the JUPITER trial in the correspondence section of the March 5, 2009 issue of the  NEJM. I collect here some of the most relevant and interesting correspondence to the editor.

“JUPITER is notable for the unacknowledged exclusion of a population that may be at increased risk for dose-related adverse effects of rosuvastatin.”

Adriane Fugh-Berman, M.D.
Georgetown University Medical Center
Washington, DC 20007
ajf29@georgetown.edu 

“JUPITER was stopped early, after a median follow-up of 1.9 years. The number of patients who would need to be treated for 2 years to prevent the occurrence of one primary end point was 95. Ridker et al. extrapolate these results by a projection over a 5-year treatment period. This estimation should be viewed critically, since the study has most of  the characteristics of a  truncated trial”.
“The majority of randomized clinical trials that are stopped early because of an observed benefit of the treatment under investigation are industry-funded drug trials that are stopped at the first interim analysis, with  the results published  in a high-impact medical journal”.

Luc A. Pierard, M.D., Ph.D.
University Hospital Sart Tilman
B 4000 Liege, Belgium
lpierard@chu.ulg.ac.be

Read the correspondence section for further comments.

Related links:

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.

laptop2


 

 

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos